The novel thioredoxin reductase inhibitor butaselen suppresses lung cancer by inducing oxidative stress.

ABSTRACT:

Background

Lung cancer is one of the leading causes of cancer-related deaths worldwide with limited treatment options available. The anti-tumor effects of the TrxR inhibitor Butaselen (BS/BS1801) on lung cancer and its underlying mechanisms remain unknown.

Methods

This study utilized lung cancer cell lines, LLC1-bearing mice models, and organoids to detect the inhibitory effects of BS on lung cancer. The ROS-induction and apoptotic role of BS on lung cancer cells and molecular mechanisms were assessed with flow cytometry, western blot, Co-IP, real-time PCR, ChIP, reporter gene assay, ELISA, and bisulfite pyrosequencing.

Results

BS can effectively inhibit lung cancer both in vitro and in vivo, by triggering ROS-induced apoptosis. The inactivation of NF-κB and MAPK sign

SUBMITTER: Chen Y 

PROVIDER: S-EPMC12667355 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature